DexCom price target raised to $82 from $80 at Baird

Baird raised the firm’s price target on DexCom to $82 from $80 and keeps a Neutral rating on the shares. The firm said they believe there’s more evidence than we previously realized that T1 market penetration may be slowing, while they also don’t see a quick or straightforward fix for the company’s DME issues, at least not without a price cut to channel partners.